Table 3.
Control A | Mild preeclampsia B | Severe preeclampsia C | P-value | Pairwise comparison | |||
---|---|---|---|---|---|---|---|
(n=24) | (n=32) | (n=32) | A vs. B | A vs. C | B vs. C | ||
Mean ±SD | Mean ±SD | Mean ±SD | |||||
BUN (mg/dl) | 11.36±2.37 | 10.71±3.26 | 10.89±3.47 | 0.726 | ns | ns | ns |
Hb (g/dl) | 11.34±1.17 | 11.47±1.64 | 11.37±1.45 | 0.932 | ns | ns | ns |
Median (Min/Max.) | Median (Min/Max.) | Median (Min/Max.) | |||||
Uric acid (mg/dL) | 4.3 (3.0/5.8)B,C | 5.6 (2.9/8.9) | 6.5 (2.6/9.6) | <0.001 | 0.001 | <0.001 | 0.052 |
WBC (103/mm3) | 10.4 (7.65/14.7) | 10.8 (7.650/23) | 11.05 (5.71/24) | 0.342 | ns | ns | ns |
PLT (103/mm3) | 220 (138/395) | 168 (125/491) | 187.5 (60/433) | 0.362 | ns | ns | ns |
AST (U/L) | 18.0 (9/53) | 15.5 (9/53) | 15 (9/52) | 0.265 | ns | ns | ns |
ALT(U/L) | 16,0 (6/58) | 15.5 (6/58) | 14.5 (6/43) | 0.271 | ns | ns | ns |
LDH (IU/L) | 227 (124/280) | 219.5 (124/380) | 255 (165/379) | 0.745 | ns | ns | ns |
Creatinine (mg/dl) | 0.7 (0.4/0.8) | 0.6 (0.4/0.8) | 0.7 (0.5/1) | 0.338 | ns | ns | ns |
Endostatin (ng/ml) X Dil.F | 17 (13/89)B,C | 41 (14/220) | 35 (25/180) | <0.001 | <0.001 | <0.001 | 0.385 |
PAPP-A (ng/ml) | 32.1 (3.9/121.4)B,C | 25.9 (2.9/67.4) | 16.3 (5.9/31.7) | 0.024 | 0.037 | 0.002 | 0.235 |
sVEGFR-1 (ng/ml) | 1.57 (1.35/4.4)B,C | 2.82 (1.52/7.97) | 3.57 (1.39/18.15) | <0.001 | <0.001 | <0.001 | 0.901 |
sVEGFR-2 (ng/ml) | 10.04 (8.63/37.92)B,C | 6.9 (4.99/14.5) | 7.03 (3.2/9.57) | <0.001 | <0.001 | 0.007 | 0.108 |
VEGF-A (ng/ml) | 10.16 (5.41/28.21)B,C | 74.93 (10.12/398.45) | 54.58 (22.75/198.38) | <0.001 | <0.001 | <0.001 | 0.303 |
fPGF (ng/ml) | 532 (133.2/1380)B,C | 349.6 (66.1/900.1) | 237.2 (2.6/716.2) | <0.001 | <0.001 | <0.001 | 0.076 |
One-way analysis of variance (ANOVA) (Robust Statistic: Brown-Forsythe); Post hoc test: Games Howell, Jonckheere-Terpstra Test (Monte Carlo); Post hoc test: Dunn’s test, Wilcoxon signed ranks test (Monte Carlo); SD – standard deviation; Min – minimum; Max – maximum; A – significant compared with the control group; B – significant compared with the mild preeclampsia group; C – significant compared with the severe preeclampsia group; WBC – white blood cells; VEGF – vascular endothelial growth factor; sVEGFR – soluble vascular endothelial growth factor receptor; PAPP-A – pregnancy-associated plasma protein-A; fPGF – free placental growth factor.